ESMO 2012: Abraxane in Pancreatic Cancer

A standing room audience at the 2012 European Society for Medical Oncology Congress in Vienna listened to a Celgene sponsored satellite symposia on Pancreatic Cancer.

1,741 total views
As seen on
  1. Pancreatic Cancer: Making an Impact through Innovation
  2. The symposium featured four leading pancreatic cancer experts: Margaret Tempero MD (University of California San Francisco), Michel Ducreux MD PhD (Institut Gustave Roussy), Manuel Hidalgo MD PhD (Universidad CEU San Pablo, Madrid) and Werner Scheithauser MD, (Medical University of Vienna) 
  3. Abraxane Phase 3 Pancreatic Trial is likely to be positive
  4. While none  of the distinguished thought leaders said it directly, their palpable excitement and enthusiasm about nab-paclitaxel (Abraxane) and frequent mentions of changes in the standard of care suggests that the phase 3 trial results, expected in the very near future, will be positive. The fair balanced review of the preclinical and clinical data for nab-paclitaxel showed clear efficacy, and no data was presented that suggested otherwise. However, we will not know for sure how effective abraxane is in pancreatic cancer until the phase 3 trial results are reported, which Celgene have said will be in Q4, 2012 or Q1, 2013.
  5. Some of the key messages from the session were shared on Twitter shortly afterwards:
  6. Abraxane will change standard of care if approved
  7. Abraxane will change the standard of care if approved for pancreatic cancer. If the data shows a doubling of survival time (or even longer) for patients with advanced disease, it will be a major breakthrough, and of sufficient magnitude to be considered for a plenary presentation at the ASCO annual meeting next year. It was exciting to be at this symposia and see a glimpse of the possible future.
  8. Update Sept 29: Abraxane data probably at ASCO GI meeting in early 2013
  9. Update Nov 10: Celgene announces that Abraxane significantly increases overall survival in pancreatic cancer trial